Changes in Hong Kong stocks | Baokangshiyun-B (02592) rose nearly 8% in the afternoon this Wednesday, the subsidiary will discuss the CBT-004 clinical development process with the US FDA

The Zhitong Finance App learned that Diakangshiyun-B (02592) rose nearly 8% in the afternoon. As of press release, it had risen 7.5% to HK$8.6, with a turnover of HK$7.6531 million.

According to the news, on the afternoon of December 8, Baokang Shiyun-B announced that Cloudbreak Therapeutics LLC (Cloudbreak USA), a wholly-owned subsidiary of the company incorporated in California, United States of America (US), is scheduled to officially hold a Phase 2 post-clinical trial meeting with the US Food and Drug Administration (US Food and Drug Administration) on December 10, 2025. The conference involves the Group's clinical-stage drug candidate CBT-004.

The company disclosed in its prospectus and interim report that CBT-004 is a potential first-of-its-kind ophthalmic drug. It uses a multikinase inhibitor to target vascular endothelial growth factor receptors and platelet-derived growth factor receptors, and is suitable for treating vascularized blepharoid fissures. The Group began phase 2 clinical trials of CBT-004 in December 2023 and completed in May 2025. The results showed that CBT-004 was safe and well tolerated in subjects, and reached the primary end point and several secondary endpoints in terms of efficacy. The Group completed the clinical trial report in July 2025 and plans to hold a phase 2 post-clinical trial meeting with the US Food and Drug Administration.

This Phase 2 post-clinical trial conference is an important milestone in the CBT-004 development process to discuss potential third-phase clinical trial development and new drug application requirements in the CBT-004 development process. The Company will issue further announcements in due course to ensure that the Company's shareholders and potential investors can keep abreast of the latest developments in the Group's business.